ResearcherWashington University in St. LouisActive in the last 2 years
Jad I. Belle
Matched on ORCID iD 0000-0001-8944-9792; OpenAlex author ID A5023076435. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2022: 1 paper · 2023: 2 papers · 2024: 1 paper
Papers 4
- Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-23-0428↗
- Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. Co-author DOI 10.1084/jem.20212062↗
- Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansio… Co-author DOI 10.1158/1078-0432.ccr-23-2993↗
- Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Co-author DOI 10.1158/1078-0432.ccr-22-0308↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- David G DeNardo · 4 shared papers, 2022–2024 · strength 0.56
- Paper Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0428↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- William G. Hawkins · 3 shared papers, 2022–2023 · strength 0.38
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Kian‐Huat Lim · 3 shared papers, 2022–2023 · strength 0.38
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Varintra E. Lander · 2 shared papers, 2023–2024 · strength 0.31
- Paper Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0428↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- John M. Baer · 2 shared papers, 2023–2024 · strength 0.31
- Paper Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0428↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Li Ding · 2 shared papers, 2023–2024 · strength 0.31
- Paper Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0428↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Ryan C Fields · 2 shared papers, 2023–2024 · strength 0.31
- Paper Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-23-0428↗
- Paper Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunothera… DOI 10.1084/jem.20212062↗
- Brett H. Herzog · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Feng Gao · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Katrina Sophia Pedersen · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Albert Craig Lockhart · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Robert R. McWilliams · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Andrea Wang‐Gillam · 2 shared papers, 2022–2023 · strength 0.24
- Paper Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer… DOI 10.1158/1078-0432.ccr-23-2993↗
- Paper Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I … DOI 10.1158/1078-0432.ccr-22-0308↗
- Blake E. Sells · 1 shared paper, 2024 · strength 0.17
- Paolo Provenzano · 1 shared paper, 2024 · strength 0.17
- Liang‐I Kang · 1 shared paper, 2024 · strength 0.17
- Guhan Qian · 1 shared paper, 2024 · strength 0.17
- Hyun Jee Kim · 1 shared paper, 2024 · strength 0.17
- Graham D. Hogg · 1 shared paper, 2023 · strength 0.14
- Chong Zuo · 1 shared paper, 2023 · strength 0.14
- Paarth B. Dodhiawala · 1 shared paper, 2023 · strength 0.14
- Daniel Cui Zhou · 1 shared paper, 2023 · strength 0.14
- C. Alston James · 1 shared paper, 2023 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.